BioAgeDiagnostics Welcomes Dr. Charles Randquist to Its Medical Advisory Board

About BioAgeDiagnostics

Strengthening clinical expertise at the intersection of longevity medicine and precision diagnostics.

CHARLOTTENLUND, DENMARK, October 26, 2026 /EINPresswire.com/ -- BioAgeDiagnostics, a precision health company focused on advanced biological ageing diagnostics and measurable health outcomes, is pleased to announce the appointment of Dr. Charles Randquist to its Medical Advisory Board.

The appointment reflects BioAgeDiagnostics' commitment to bridging emerging advances in ageing biology and preventive medicine, supporting healthcare professionals in translating complex molecular insights into meaningful, personalised health strategies.

Dr. Randquist brings extensive experience as a medical practitioner, with 30 years of experience within aesthetic and reconstructive plastic surgery and 8 years within preventive health, regenerative and longevity medicine as founder of the prestigious Victoriakliniken and Dr.C-Health.
As a member of the Medical Advisory Board, Dr. Randquist will contribute his clinical perspective to BioAgeDiagnostics' ongoing development of an integrated, multi-omics approach to longevity medicine.

Moving Beyond a Single Biological Age Number
Biological ageing is a complex, multidimensional process involving changes across molecular, cellular and physiological systems. While advances in epigenetics, proteomics, metabolomics and other biomarker technologies are creating new opportunities to characterise aspects of biological ageing, translating these measurements into clinically meaningful decisions remains an important scientific challenge.

BioAgeDiagnostics is addressing this challenge through a diagnostic portfolio that brings together complementary biological data layers, including epigenetic ageing assessments, proteomic biomarkers, metabolic health, immune ageing, microbiome profiling and genetic insights.
The objective is to support a more comprehensive understanding of individual biological health, establish measurable baselines and facilitate longitudinal assessment of biomarker changes.

Strengthening the Clinical Foundations of Longevity Medicine
Dr. Randquist will support BioAgeDiagnostics' focus on scientific credibility, clinical relevance and the responsible integration of advanced diagnostics into preventive and personalised healthcare.

The future of healthcare is precision health, and advances in molecular diagnostics are making this vision increasingly achievable. Through our curated portfolio of complementary diagnostic technologies, we enable clinicians to understand individual biology across multiple molecular pathways and physiological systems. But the true value lies in translating these multidimensional biological insights into informed clinical decisions — identifying opportunities for earlier prevention, personalising interventions and longitudinal outcomes. Welcoming Dr. Charles Randquist to our Medical Advisory Board further strengthens our commitment to bridging scientific innovation and clinical practice, making precision longevity medicine actionable, measurable and scalable
— Bettina, Co-Founder & Managing Partner, BioAgeDiagnostics

From a clinical perspective, the challenge is no longer simply gaining access to advanced diagnostics, but understanding which measurements are relevant for each patient, how to interpret them in the context of their overall health, and when those findings should inform clinical action. Molecular biomarkers can provide valuable insights, but they must be considered alongside medical history, established clinical markers and physiological function. Equally important is monitoring patients over time to determine whether personalised interventions translate into meaningful improvements in health.

As interest in longevity medicine continues to grow internationally, BioAgeDiagnostics is working to connect emerging biomarker science with the practical needs of healthcare professionals. The company's approach is centred on integrating complementary diagnostic technologies and supporting longitudinal measurement, while recognising the distinction between changes in biomarkers and demonstrated improvements in clinical outcomes.
With Dr. Randquist joining its Medical Advisory Board, BioAgeDiagnostics continues to build the clinical and scientific expertise needed to support the responsible development and adoption of precision longevity diagnostics.

About BioAgeDiagnostics
BioAgeDiagnostics is a European precision health and longevity company translating advances in ageing biology, molecular diagnostics and multi-omics technologies into clinically relevant insights.
We enable healthcare professionals to operationalise and scale longevity medicine through a ready-to-implement framework combining curated advanced diagnostics, longevity therapeutics, clinical protocols and integrated operational infrastructure.
Our portfolio spans genomics, epigenetics, proteomics, metabolomics, immune ageing, microbiome analysis and clinical biomarkers.
By simplifying clinical and commercial workflows, we empower healthcare providers to deliver personalised, data-driven longevity programmes without the operational complexity or resources typically required to scale.
Our mission is to advance proactive, personalised and measurable healthcare that supports longer, healthier lives.

Website: www.bioagediagnostics.com
Media enquiries
BioAgeDiagnostics
info@bioagediagnostics.com
www.bioagediagnostics.com

Bettina van Wylich-muxoll
BioAgeDiagnostics
+45 22 70 47 24